Up­stream and CAMP4 tar­get $182M, $67M IPOs

Up­stream Bio, a mid-stage res­pi­ra­to­ry drug de­vel­op­er, and CAMP4 Ther­a­peu­tics, a Phase 1 reg­u­la­to­ry RNA start­up, have un­veiled the tar­get­ed price ranges for their ini­tial …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER